LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased or otherwise acquired Immunomedics shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
Immunomedics is a biopharmaceutical company that is engaged in the development of monoclonal antibody-based products for the treatment of cancer. The investigation concerns whether the Company violated the Securities Exchange Act of 1934. On July 28, 2015, Immunomedic’s collaboration partner announced that their drug had failed two Phase 3 studies. When this news reached the investing public, shares of the Company fell causing investors harm.
If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.